PharmaTimesOriginal article
Carvykti delivers five-year remissions in early myeloma
Data ReadoutpositiveCarvyktiPositive
AI Analysis
Summary
Carvykti (CAR-T therapy) demonstrated positive five-year follow-up data in multiple myeloma with 50% of patients maintaining progression-free status without requiring maintenance therapy, representing a significant clinical milestone for the cell therapy.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Five-year remission data showing 50% of patients remained progression-free without maintenance therapy
Importance:7/10
Sentiment:
0.75
CAR-Tmultiple myelomalong-term dataremissioncell therapy
Read the original article
Published by PharmaTimes on September 28, 2026 10:27 AM